BPG is committed to discovery and dissemination of knowledge
Basic Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. May 27, 2026; 18(5): 115659
Published online May 27, 2026. doi: 10.4254/wjh.v18.i5.115659
Kaempferol attenuates diet-induced obesity and hepatic steatosis in C57BL/6J mice fed an Indian diet-mimicking regimen
Bhagyalakshmi Nair, Rajesh Gopalakrishna, Lekshmi R Nath
Bhagyalakshmi Nair, Lekshmi R Nath, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, Kerala, India
Rajesh Gopalakrishna, Department of Gastroenterology, Amrita Institute of Medical Sciences and Research Centre, Kochi 682041, Kerala, India
Author contributions: Nair B contributed to writing-original draft, resources, software, and data curation; Gopalakrishna R and Nath LR contributed to writing-review and editing, visualization, and validation; Nair B and Gopalakrishna R contributed to investigation; Nair B and Nath LR contributed to methodology and formal analysis; Nath LR contributed to conceptualization, supervision, project administration, and funding acquisition.
Supported by the Amrita Vishwa Vidyapeetham Seed Grant, No. K-PHAR-22-662.
Institutional animal care and use committee statement: The experimental protocol was approved by the Institutional Animal Ethics Committee, No. IAEC/2020/1/7. All animal procedures were performed in accordance with the guidelines set by Committee for the Control and Supervision of Animal Experiments.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The authors confirm that the data supporting this study is included within the manuscript.
Corresponding author: Lekshmi R Nath, PhD, Associate Professor, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Ponekkara PO, Kochi 682041, Kerala, India. lekshmirnath@aims.amrita.edu
Received: October 24, 2025
Revised: December 1, 2025
Accepted: February 4, 2026
Published online: May 27, 2026
Processing time: 216 Days and 16 Hours
Core Tip

Core Tip: Metabolic dysfunction-associated steatotic liver disease spans from simple fat accumulation to cirrhosis and liver cancer, and its prevalence is steadily rising in India due to high fat, high sugar dietary habits. Kaempferol, a generally recognized as safe-approved flavonoid lipid-lowering effects, shows therapeutic potential but has not yet been evaluated in Indian diet-specific obesity driven liver disease models. This study demonstrates that kaempferol effectively attenuates diet-induced obesity and liver steatosis in C57BL/6J mice fed an Indian diet-mimicking regimen. The findings highlight kaempferol’s potential as a natural therapeutic agent for managing metabolic dysfunction and fatty liver disease associated with high calorie, region-specific dietary patterns.

Write to the Help Desk